Kim D C, Harrison A W, Ruwart M J, Wilkinson K F, Fisher J F, Hidalgo I J, Borchardt R T
Department of Pharmaceutical Chemistry, University of Kansas, Lawrence 66045.
J Drug Target. 1993;1(4):347-59. doi: 10.3109/10611869308996094.
To evaluate the bile acid transporter as a means of enhancing the ability of renin-inhibitory peptides (RIPs) to penetrate the intestinal mucosa, two RIP-cholic acid conjugates and an RIP-taurocholic acid conjugate were synthesized. Conjugation was through the N-terminus of an RIP and the 3-position of the bile acid, via a six-carbon spacer. An RIP derivative containing the spacer without the bile acid moiety was also synthesized. The bile acid-RIP conjugates and the RIP derivative were shown to be potent inhibitors of human renin in vivo and to have in vivo hypotensive activity equivalent to that of the parent RIP (ditekiren) in a human renin-infused rat model. The ability of these RIP derivatives to bind to the bile acid transporter and be transported across an epithelial cell monolayer was evaluated in an in vitro model of the intestinal mucosa consisting of Caco-2 cell monolayers grown on microporous membranes. One of the RIP-cholic acid conjugate (KI = 60 +/- 10 microM) and the RIP-taurocholic acid conjugate (KI = 19 +/- 5 microM), but not the RIP derivative, were shown to be potent inhibitors of the apical (AP) to basolateral (BL) transport of [14C]-taurocholic acid ([14C]-TA). At concentrations up to 250 microM these RIP-bile acid conjugates had no effect on the diffusion of [3H]-PEG (800-1000), which is a marker of the paracellular pathway. The permeability coefficients of the RIP-bile acid conjugates, determined using Caco-2 cell monolayers, were shown to be six times less than that of [3H]-PEG (800-1000). In addition, the transport of one of the RIP-cholic acid conjugates was investigated in perfused rat ileum in which the mesenteric vein was cannulated. The conjugate was not detected in blood samples taken from the mesenteric vein, while its concentration in intestinal perfusate remained almost constant during the perfusion experiment. These results suggest that while the peptide-bile acid conjugates retain binding affinity for the intestinal bile acid transporter, the molecules are not themselves transported.
为了评估胆汁酸转运体作为增强肾素抑制肽(RIPs)穿透肠黏膜能力的一种手段,合成了两种RIP-胆酸共轭物和一种RIP-牛磺胆酸共轭物。共轭是通过RIP的N端和胆汁酸的3位,经由一个六碳间隔基进行的。还合成了一种含有间隔基但不含胆汁酸部分的RIP衍生物。在输注人肾素的大鼠模型中,胆汁酸-RIP共轭物和RIP衍生物在体内显示出是有效的人肾素抑制剂,并且具有与母体RIP(替替瑞伦)相当的体内降压活性。在由生长于微孔膜上的Caco-2细胞单层组成的肠黏膜体外模型中,评估了这些RIP衍生物与胆汁酸转运体结合并跨上皮细胞单层转运的能力。其中一种RIP-胆酸共轭物(KI = 60±10微摩尔)和RIP-牛磺胆酸共轭物(KI = 19±5微摩尔),而非RIP衍生物,显示出是[14C]-牛磺胆酸([14C]-TA)从顶端(AP)到基底外侧(BL)转运的有效抑制剂。在浓度高达250微摩尔时,这些RIP-胆汁酸共轭物对[3H]-聚乙二醇(800 - 1000)的扩散没有影响,[3H]-聚乙二醇(800 - 1000)是细胞旁途径的标志物。使用Caco-2细胞单层测定的RIP-胆汁酸共轭物的渗透系数显示比[3H]-聚乙二醇(800 - 1000)低六倍。此外,在肠系膜静脉插管的灌注大鼠回肠中研究了其中一种RIP-胆酸共轭物的转运。在从肠系膜静脉采集的血样中未检测到该共轭物,而在灌注实验期间其在肠灌流液中的浓度几乎保持恒定。这些结果表明,虽然肽-胆汁酸共轭物对肠胆汁酸转运体保留结合亲和力,但这些分子本身并未被转运。